BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22388842)

  • 21. [Extracorporeal photochemotherapy: review of its mechanisms of action and clinical applications].
    Vanheste S; Vereecken P; Lambermont M; Heenen M; Bron D
    Rev Med Brux; 2007; 28(5):445-51. PubMed ID: 18069519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extracorporeal photopheresis: from solid organs to face transplantation.
    Hivelin M; Siemionow M; Grimbert P; Lantieri L
    Transpl Immunol; 2009 Jul; 21(3):117-28. PubMed ID: 19409991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of action of extracorporeal photochemotherapy.
    Heshmati F
    Transfus Apher Sci; 2003 Aug; 29(1):61-70. PubMed ID: 12877896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of extensive chronic graft-versus-host disease with extracorporeal photochemotherapy.
    Bisaccia E; Palangio M; Gonzalez J; Adler KR; Scarborough R; Goldberg SL; Rowley SD
    J Clin Apher; 2006 Oct; 21(3):181-7. PubMed ID: 16607632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Extracorporeal photochemotherapy].
    Viguier M; Pouthier F; Tiberghien P; Aubin F
    Transfus Clin Biol; 2010 Feb; 17(1):28-33. PubMed ID: 20042357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Photopheresis: new immunomodulatory therapy for T-lymphocite mediated diseases].
    Vagace Valero JM; Alonso Escobar N; De Argila Fernández-Durán D; Vargas Pérez L; Melero Ruiz J; Morán Penco JM; Bajo Gómez R; Pérez Miranda M
    An Med Interna; 2003 Aug; 20(8):421-6. PubMed ID: 14516265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mode of action, indications and recommendations on extracorporeal photopheresis (ECP).
    Cho A; Paulitschke V; Knobler R
    J Dtsch Dermatol Ges; 2023 Nov; 21(11):1369-1380. PubMed ID: 37723908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Therapeutic experiences with extracorporeal photopheresis. Technical procedure, follow-up and clinical outcome in 31 skin diseases].
    Owsianowski M; Garbe C; Ramaker J; Orfanos CE; Gollnick H
    Hautarzt; 1996 Feb; 47(2):114-23. PubMed ID: 8868455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Photopheresis: Advances and Use in Systemic Sclerosis.
    Zhou XA; Choi J
    Curr Rheumatol Rep; 2017 Jun; 19(6):31. PubMed ID: 28466383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A concise review on extracorporeal photochemotherapy: Where we began and where we are now and where are we going!
    Perotti C; Sniecinski I
    Transfus Apher Sci; 2015 Jun; 52(3):360-8. PubMed ID: 25910538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical and flow cytometry outcome of improved photopheresis methods in dermatologic patients].
    Ullrich H; Stolz W; Barlage S; Lackner KJ; Rothe G; Schmitz G
    Beitr Infusionsther Transfusionsmed; 1997; 34():256-64. PubMed ID: 9417345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extracorporeal photopheresis: a review.
    Oliven A; Shechter Y
    Blood Rev; 2001 Jun; 15(2):103-8. PubMed ID: 11409910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Donor lymphocyte infusions combined with systemic PUVA/bexarotene as an effective bimodal immunologic approach in a patient with relapsed cutaneous T cell lymphoma after allogeneic stem cell transplantation.
    Schlaak M; Kurschat P; Shimabukuro-Vornhagen A; Scheid C; Chemnitz J; Stadler R; von Bergwelt-Baildon M; Theurich S
    Transpl Immunol; 2011 Sep; 25(2-3):163-6. PubMed ID: 21745569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ECP versus PUVA for the treatment of cutaneous T-cell lymphoma.
    Geskin L
    Skin Therapy Lett; 2007 Jun; 12(5):1-4. PubMed ID: 17609808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.
    Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P
    Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The North American experience with photopheresis.
    Zic JA; Miller JL; Stricklin GP; King LE
    Ther Apher; 1999 Feb; 3(1):50-62. PubMed ID: 10079806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The Hellenic experience.
    Siakantaris MP; Tsirigotis P; Stavroyianni N; Argyropoulos KV; Girkas K; Pappa V; Chondropoulos S; Papadavid E; Sakellari I; Anagnostopoulos A; Antoniou C; Dervenoulas J
    Transfus Apher Sci; 2012 Apr; 46(2):189-93. PubMed ID: 22178592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Technology insight: ECP for the treatment of GvHD--can we offer selective immune control without generalized immunosuppression?
    Marshall SR
    Nat Clin Pract Oncol; 2006 Jun; 3(6):302-14. PubMed ID: 16757968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extracorporeal photoimmunotherapy-photopheresis.
    Dani T; Knobler R
    Front Biosci (Landmark Ed); 2009 Jan; 14(12):4769-77. PubMed ID: 19273388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Extracorporeal photopheresis].
    Hsieh A; Cortés B
    Rev Med Suisse; 2018 Mar; 14(600):699-702. PubMed ID: 29589657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.